All Stories

AbbVie regained TV ad spending lead amid February slowd...

After Novartis’ Pluvicto shook up iSpot.TV’s monthly rankings of the top TV adve...

Johnson & Johnson CEO Joaquin Duato takes a 14% pay cut...

In his third year as the CEO of Johnson & Johnson, Joaquin Duato received an ove...

Johnson & Johnson CEO Duato takes a 14% pay cut to $24.3M

In his third year as the CEO of Johnson & Johnson, Joaquin Duato received an ove...

Merck defeats claims it should have added safety warnin...

In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simul...

Canada's Entos Pharmaceuticals plots $137M R&D, manufac...

The facility will be used to develop and produce Entos' Fusogenix proteolipid ve...

A once-yearly PrEP? Gilead's lenacapavir shows promise ...

After Gilead’s lenacapavir made waves with stellar clinical results as a twice-y...

A once-yearly PrEP? Gilead’s lenacapavir shows promise ...

After Gilead’s lenacapavir made waves with stellar clinical results as a twice-y...

Merck opens $1B Gardasil manufacturing facility in Nort...

At its sprawling manufacturing complex in Durham, N.C., Merck has opened a new $...

As Humira succession plan played out, AbbVie's Rob Mich...

For his work in 2024, AbbVie helmsman Robert Michael—who took over the CEO post ...

With AbbVie in its sights, Tenpoint names commercial ch...

Tenpoint Therapeutics has tasked Carol Kearney with cracking a market that confo...

Knight Therapeutics stacks its Canadian armor with $99M...

The deal, which is expected to close in mid-2025, marks the divesture of Endo's ...

Viking pays $150M to recruit CordenPharma for obesity d...

Obesity upstart Viking Therapeutics has agreed to pay a total of $150 million th...

In buying cell therapy partner 2seventy bio for $286M, ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell ...

CDMO Almac continues expansion spree with new £65M UK o...

The opening of the new 100,000-square-foot facility at Almac's headquarters in C...

Indian contractor Syngene throws down $37M for Emergent...

Indian CRDMO Syngene International is paying $36.5 million to acquire Emergent B...

By exercising long-held stock options, BioNTech CEO sco...

In exercising some of his stock options in 2024, BioNTech CEO Uğur Şahin, M.D., ...

Roche overhauls Spark gene therapy unit, recording $2.4...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics...

Starboard CEO gets seat on Kenvue's board as activist i...

Activist investor Starboard Value proposed four additions to Kenvue's board last...

Starboard CEO gets seat on Kenvue's board as activist i...

Activist investor Starboard Value proposed four additions to Kenvue's board last...

Incyte's mixed Opzelura data in prurigo nodularis add u...

Incyte's Opzelura was successful in just one of two parallel phase 3 trials asse...

GSK, Novartis, Lilly among Big Pharmas celebrating Inte...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—...

On the heels of FDA nod for cancer drug, Sun Pharma buy...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint...

With Eli Lilly flying high, CEO David Ricks collects 10...

Presiding over the upward trajectory of Eli Lilly over the last eight years has ...

Neurotech nabs FDA approval to treat rare eye disorder ...

The FDA last week approved Neurotech’s cell therapy implant revakinagene taroret...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.